ONCOCYTE CORP

ONCOCYTE CORP (OCX)

$0.2196

-0.01

(-3.56%)

Market is closed - opens 7 PM, 05 Jun 2023

Insights on ONCOCYTE CORP

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 2.06M → -3.55M (in $), with an average decrease of 166.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -8.3M → -44.97M (in $), with an average decrease of 131.5% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 21.6% return, outperforming this stock by 99.9%

  • Vs IDXX

    In the last 3 years, Idexx Laboratories, Inc. has given 48.5% return, outperforming this stock by 139.9%

Performance

  • $0.21
    $0.23
    $0.22
    downward going graph

    4.55%

    Downside

    Day's Volatility :7.16%

    Upside

    2.74%

    downward going graph
  • $0.20
    $1.35
    $0.22
    downward going graph

    9.09%

    Downside

    52 Weeks Volatility :85.19%

    Upside

    83.7%

    downward going graph

Returns

PeriodONCOCYTE CORPSector (Health Care)Index (Russel 2000)
3 Months
-37.1%
0.7%
-7.0%
6 Months
-54.35%
-7.9%
-6.5%
1 Year
-78.31%
-2.0%
-6.8%
3 Years
-91.41%
25.4%
24.7%

Highlights

Market Capitalization
36.2M
Book Value
$0.32
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.09
PEG Ratio
0.0
Wall Street Target Price
0.35
Profit Margin
0.0%
Operating Margin TTM
-3129.37%
Return On Assets TTM
-14.94%
Return On Equity TTM
-18.4%
Revenue TTM
875.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-21.8%
Gross Profit TTM
188.0K
EBITDA
-22.9M
Diluted Eps TTM
-0.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.13
EPS Estimate Next Year
-0.2
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for ONCOCYTE CORP(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 59.38%

Current $0.22
Target $0.35

Technicals Summary

Sell

Neutral

Buy

ONCOCYTE CORP is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
ONCOCYTE CORP
ONCOCYTE CORP
-15.01%
-54.35%
-78.31%
-91.41%
-91.41%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
0.53%
7.93%
21.61%
48.46%
114.73%
Agilent Technologies Inc.
Agilent Technologies Inc.
-13.57%
-25.32%
-9.95%
28.76%
83.43%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.49%
-7.75%
-8.9%
48.36%
142.51%
Danaher Corp.
Danaher Corp.
-4.16%
-15.15%
-14.85%
39.37%
128.42%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
7.2%
-8.62%
-9.58%
31.31%
96.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
ONCOCYTE CORP
ONCOCYTE CORP
NA
NA
0.0
-0.13
-0.18
-0.15
0.0
0.32
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
56.2
56.2
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
26.91
26.91
2.36
5.63
0.25
0.1
0.01
18.96
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
33.19
33.19
4.28
23.68
0.14
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
24.72
24.72
3.24
9.38
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
35.16
35.16
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
ONCOCYTE CORP
ONCOCYTE CORP
Buy
$36.2M
-91.41%
NA
0.0%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$38.6B
114.73%
56.2
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$35.3B
83.43%
26.91
19.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$196.1B
142.51%
33.19
13.75%
Danaher Corp.
Danaher Corp.
Buy
$169.4B
128.42%
24.72
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$36.5B
96.53%
35.16
7.28%

Institutional Holdings

  • BROADWOOD CAPITAL Inc

    14.19%
  • PURA VIDA INVESTMENTS, LLC

    10.97%
  • Awm Investment Company Inc

    4.41%
  • Vanguard Group Inc

    2.65%
  • Defender Capital, LLC.

    1.44%
  • BlackRock Inc

    0.86%

Corporate Announcements

  • ONCOCYTE CORP Earnings

    ONCOCYTE CORP’s price-to-earnings ratio stands at None

    Read More

Company Information

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

Organization
ONCOCYTE CORP
Employees
75
CEO
Dr. Douglas T. Ross M.D., Ph.D.
Industry
Health Technology

FAQs